With substantial progress in developing its differentiated and innovative CGM and its significant market potential, Trinity Biotech’s board and management have determined that CGM technology and ...

Trinity Biotech (Nasdaq:TRIB) today announced the next stage of its transformation plan as it looks to bring a CGM to market.

Trinity Biotech is also preparing for additional pre-pivotal clinical trials in Q1 2025 to test further device enhancements ... U.S. government funding for its HIV testing programs, despite ...

Trinity Biotech (TRIB) announces the next stage in realizing its comprehensive transformation plan and development of its continuous glucose ...

the company is now increasing its expected 2024 sales revenue for TrinScreen HIV to approximately $10 million, up from $8 million. President and Chief Executive Officer of Trinity Biotech ...

Trinity Biotech stock surges on high volume after announcing increased orders for TrinScreen HIV, boosting 2024 revenue projections to $10 million. Second-quarter earnings show a 14% YoY revenue ...

However, Trinity Biotech is currently assessing the impact of a U.S. executive order that has paused funding for foreign assistance programs, potentially affecting its rapid HIV test sales.

(RTTNews) - Trinity Biotech plc (TRIB), a biotechnology company focused on diabetes management, on Thursday announced notable advances in its pre-pivotal trial for its next-generation continuous ...